ES2305567T3 - Formulaciones de tramadol de liberacion sostenida con una eficacia de 24 horas. - Google Patents

Formulaciones de tramadol de liberacion sostenida con una eficacia de 24 horas. Download PDF

Info

Publication number
ES2305567T3
ES2305567T3 ES03809237T ES03809237T ES2305567T3 ES 2305567 T3 ES2305567 T3 ES 2305567T3 ES 03809237 T ES03809237 T ES 03809237T ES 03809237 T ES03809237 T ES 03809237T ES 2305567 T3 ES2305567 T3 ES 2305567T3
Authority
ES
Spain
Prior art keywords
hours
release
formulations
effectiveness
sustained
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES03809237T
Other languages
English (en)
Inventor
Vincent Lenaerts
Patricia Laure Ouadji-Njiki
Jonathan Bacon
Rachid Ouzerourou
Sonia Gervais
Miloud Rahmouni
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Labopharm Barbados Ltd
Labopharm Inc
Paladin Labs Europe Ltd
Original Assignee
Labopharm Barbados Ltd
Labopharm Inc
Paladin Labs Europe Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Labopharm Barbados Ltd, Labopharm Inc, Paladin Labs Europe Ltd filed Critical Labopharm Barbados Ltd
Application granted granted Critical
Publication of ES2305567T3 publication Critical patent/ES2305567T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin

Abstract

Formulación de dosificación sólida que comprende: un núcleo que comprende un principio farmacéutico activo (API) y una matriz y un recubrimiento que comprende una mezcla física de acetato de polivinilo y polivinilpirrolidona y un principio farmacéutico activo, en la que el principio farmacéutico activo y la matriz del núcleo están asociados de manera que la liberación del principio farmacéutico desde la matriz del núcleo es controlada, de manera que la liberación desde la formulación del principio activo dispuesto en el núcleo resulta más lenta que la liberación del principio farmacéutico activo dispuesto en la matriz del recubrimiento, en la que el principio farmacéutico activo del núcleo y del recubrimiento es el mismo y es tramadol o un estereoisómero o su sal farmacéuticamente aceptable.
ES03809237T 2002-10-25 2003-10-27 Formulaciones de tramadol de liberacion sostenida con una eficacia de 24 horas. Expired - Lifetime ES2305567T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50906202P 2002-10-25 2002-10-25
US51037803P 2003-10-10 2003-10-10

Publications (1)

Publication Number Publication Date
ES2305567T3 true ES2305567T3 (es) 2008-11-01

Family

ID=35044187

Family Applications (1)

Application Number Title Priority Date Filing Date
ES03809237T Expired - Lifetime ES2305567T3 (es) 2002-10-25 2003-10-27 Formulaciones de tramadol de liberacion sostenida con una eficacia de 24 horas.

Country Status (12)

Country Link
US (1) US7988998B2 (es)
EP (1) EP1594460B1 (es)
AT (1) ATE390128T1 (es)
BR (1) BR0315659A (es)
DE (1) DE60320039T2 (es)
DK (1) DK1594460T3 (es)
ES (1) ES2305567T3 (es)
HK (1) HK1101355A1 (es)
MX (1) MXPA05004412A (es)
NZ (1) NZ539870A (es)
SI (1) SI1594460T1 (es)
TW (1) TWI319713B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI319713B (en) * 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) * 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
US20060172006A1 (en) * 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
KR101655455B1 (ko) * 2005-09-09 2016-09-07 안젤리니 라보팜 엘엘씨 일일 1회 투여를 위한 트라조돈 조성물
AU2008314454A1 (en) * 2007-10-16 2009-04-23 Labopharm (Barbados) Limited Bilayer composition for the sustained release of acetaminophen and tramadol
JP5651818B2 (ja) 2007-12-17 2015-01-14 パラディン ラブス インコーポレーテッド 誤用を防止するための放出制御製剤
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
CA2746888C (en) 2008-12-16 2015-05-12 Labopharm (Barbados) Limited Misuse preventative, controlled release formulation
US8623409B1 (en) 2010-10-20 2014-01-07 Tris Pharma Inc. Clonidine formulation
KR102380825B1 (ko) * 2015-05-29 2022-04-01 삼성전자주식회사 반도체 발광다이오드 칩 및 이를 구비한 발광장치
PT3431078T (pt) * 2017-07-20 2021-04-21 Intas Pharmaceuticals Ltd Composições orais sólidas de libertação prolongada não pulsáteis de betaistina
US11918689B1 (en) 2020-07-28 2024-03-05 Tris Pharma Inc Liquid clonidine extended release composition

Family Cites Families (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2987445A (en) * 1958-10-10 1961-06-06 Rohm & Haas Drug composition
US3087860A (en) * 1958-12-19 1963-04-30 Abbott Lab Method of prolonging release of drug from a precompressed solid carrier
US3336200A (en) * 1963-05-28 1967-08-15 Warner Lambert Pharmaceutical Tablet structure
IT1066857B (it) * 1965-12-15 1985-03-12 Acraf Derivati della s ipiazolo 4.3 a piridina e processi per la loro preparazione
US3652589A (en) * 1967-07-27 1972-03-28 Gruenenthal Chemie 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols
GB1368574A (en) 1971-02-12 1974-10-02 Ives Lab Inc Divisible tablet
US4131675A (en) 1978-02-09 1978-12-26 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Use of combinations of L-DOPA with trazodone and L-DOPA with etoperidone in Parkinsonism
US4820522A (en) * 1987-07-27 1989-04-11 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
US5004613A (en) * 1987-07-27 1991-04-02 Mcneil-Ppc, Inc. Oral sustained release pharmaceutical formulation and process
IT1233412B (it) * 1987-12-02 1992-03-30 Acraf Uso del trazodone
US4938968A (en) * 1988-07-26 1990-07-03 Norjec Development Associates, Inc. Controlled release indomethacin
US5133974A (en) * 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5603956A (en) * 1990-11-27 1997-02-18 Labopharm Inc. Cross-linked enzymatically controlled drug release
CA2041774C (en) 1990-11-27 1994-04-19 Mircea A. Mateescu Use of cross-linked amylose as a matrix for the slow release of biologically active compounds
EP0566709B3 (en) * 1991-09-06 2009-04-08 Ortho-McNeil-Janssen Pharmaceuticals, Inc. Composition comprising a tramadol compound and acetaminophen, and its use
US5407686A (en) * 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5273760A (en) 1991-12-24 1993-12-28 Euroceltigue, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5286493A (en) * 1992-01-27 1994-02-15 Euroceltique, S.A. Stabilized controlled release formulations having acrylic polymer coating
GB2284760B (en) 1993-11-23 1998-06-24 Euro Celtique Sa A method of preparing pharmaceutical compositions by melt pelletisation
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
FR2688422A1 (fr) 1992-03-11 1993-09-17 Coletica Microcapsules a parois en polysaccharides contenant des fonctions alcools primaires, et compositions en contenant.
US5292534A (en) * 1992-03-25 1994-03-08 Valentine Enterprises, Inc. Sustained release composition and method utilizing xanthan gum and an active ingredient
ATE137668T1 (de) 1992-07-24 1996-05-15 Labopharm Inc Vernetztes polyhydroxyl-material zur enzymatisch gesteuerten arzneistofffreisetzung
SE9202250D0 (sv) * 1992-07-29 1992-07-29 Gacell Lab Ab Controlled release morphine preparation
IL103096A (en) * 1992-09-08 1996-12-05 Chemagis Ltd Process for purification 2 -]) Dimethylamino (methyl-1-) 3-methoxycinyl (cyclohexanol and its salts.
FR2698560B1 (fr) * 1992-11-30 1995-02-03 Virbac Laboratoires Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications.
US5616343A (en) * 1993-03-25 1997-04-01 Labopharm, Inc. Cross-linked amylose as a binder/disintegrant in tablets
IL119660A (en) * 1993-05-10 2002-09-12 Euro Celtique Sa Controlled release formulation comprising tramadol
DE4315525B4 (de) 1993-05-10 2010-04-15 Euro-Celtique S.A. Pharmazeutische Zusammensetzung
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
IL109944A (en) 1993-07-01 1998-12-06 Euro Celtique Sa Continuous release dosage form containing morphine and a method of preparing such sustained release unit dosage forms
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
ES2113673T3 (es) * 1993-08-24 1998-05-01 Akzo Nobel Nv Lentes oftalmicas.
DE4329794C2 (de) 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
KR100354702B1 (ko) 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
ATE212224T1 (de) 1993-11-23 2002-02-15 Euro Celtique Sa Verfahren zur herstellung einer arzneizusammensetzung mit verzögerter wirkstoffabgabe
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US6210714B1 (en) * 1993-11-23 2001-04-03 Euro-Celtique S.A. Immediate release tablet cores of acetaminophen having sustained-release coating
US5843480A (en) 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5560331A (en) 1994-05-10 1996-10-01 Yamaha Hatsudoki Kabushiki Kaisha Cylinder head for engine
GB2290965A (en) * 1994-07-11 1996-01-17 Therapicon Srl Multiple layer capsules for drugs
US6586006B2 (en) * 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
EP0807433A4 (en) 1994-12-27 2005-12-28 Akzo Nobel Nv PREPARING WITH DELAYED RELEASE
US5981592A (en) 1995-03-13 1999-11-09 Loma Linda University Medical Center Method and composition for treating cystic fibrosis
US6214331B1 (en) * 1995-06-06 2001-04-10 C. R. Bard, Inc. Process for the preparation of aqueous dispersions of particles of water-soluble polymers and the particles obtained
DE19530575A1 (de) * 1995-08-19 1997-02-20 Gruenenthal Gmbh Schnell zerfallende Arzneiform von Tramadol oder einem Tramadolsalz
GB9519363D0 (en) * 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
IL116281A (en) * 1995-12-07 1999-06-20 Chemagis Ltd Process for the purification of (rr,ss)-2-dimethylaminomethyl-1-(3-methoxyphenyl) cyclohexanol and its salts
IT1282650B1 (it) * 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
US5773031A (en) * 1996-02-27 1998-06-30 L. Perrigo Company Acetaminophen sustained-release formulation
CA2173818A1 (fr) * 1996-04-10 1997-10-11 Francois Chouinard Comprime pharmaceutique a liberation controlee contenant un support a base d'amylose reticule et d'hydroxypropylmethylcellulose
IL119121A (en) * 1996-08-22 2000-11-21 Chemagis Ltd Process for the purification of (RR-SS)-2-dimethylaminomethyl-1-(3-methoxyphenyl)cyclohexanol hydrochloride
DE19640062B4 (de) 1996-09-28 2006-04-27 Lts Lohmann Therapie-Systeme Ag Orale Zubereitung, enthaltend in einer in wässrigem Medium quellbaren Matrix wenigstens einen pharmazeutischen Wirkstoff
CA2269806C (en) 1996-10-28 2006-01-24 Bernhard H. Van Lengerich Embedding and encapsulation of controlled release particles
US5879707A (en) * 1996-10-30 1999-03-09 Universite De Montreal Substituted amylose as a matrix for sustained drug release
IE970892A1 (en) * 1996-12-18 2000-02-09 Bimeda Res And Dev Ltd A veterinary composition
US5807575A (en) * 1997-02-14 1998-09-15 Rougier Inc. Manufacture of cross-linked amylose useful as a excipient for control release of active compounds
DE19710008A1 (de) 1997-03-12 1998-09-17 Basf Ag Feste, mindestens zweiphasige Zubereitungsformen eines Opioid-Analgeticums mit verzögerter Freisetzung
BE1011045A3 (fr) * 1997-03-14 1999-04-06 Ucb Sa Compositions pharmaceutiques pour la liberation controlee de substances actives.
AU8293498A (en) 1997-07-02 1999-01-25 Euro-Celtique S.A. Stabilized sustained release tramadol formulations
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US5877351A (en) * 1997-12-24 1999-03-02 Wyckoff Chemical Company, Inc. Preparation and purification process for 2- (dimethylamino) methyl!-1-(3-methoxphenyl)-cyclohexanol and its salts
WO1999038504A1 (en) * 1998-01-29 1999-08-05 Sepracor Inc. Pharmaceutical uses of optically pure (-)-bupropion
US6284273B1 (en) * 1998-02-24 2001-09-04 Vincent Lenaerts Cross-linked high amylose starch resistant to amylase as a matrix for the slow release of biologically active compounds
US6245357B1 (en) * 1998-03-06 2001-06-12 Alza Corporation Extended release dosage form
DE1073432T1 (de) 1998-04-14 2002-02-07 Gen Hospital Corp Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden
US6156342A (en) 1998-05-26 2000-12-05 Andex Pharmaceuticals, Inc. Controlled release oral dosage form
US6143325A (en) 1998-06-05 2000-11-07 Bristol-Myers Squibb Company Nefazodone dosage form
WO2000002523A2 (en) 1998-07-10 2000-01-20 U.S. Medical Research Institute Of Infectious Diseases Department Of The Army Vaccine against staphylococcus intoxication
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
US6245387B1 (en) * 1998-11-03 2001-06-12 Diamon-Fusion International, Inc. Capped silicone film and method of manufacture thereof
US6129205A (en) 1998-12-09 2000-10-10 Ashworth Bros. Inc. Variable loop count conveyor belt
DE19901683B4 (de) 1999-01-18 2005-07-21 Grünenthal GmbH Analgetikum mit kontrollierter Wirkstofffreisetzung
DE19901686A1 (de) 1999-01-18 2000-07-20 Gruenenthal Gmbh Retardierte Tramadolzubereitungen mit einem lagerstabilen Freisetzungsprofil und Verfahren zu deren Herstellung
PE20001396A1 (es) * 1999-01-18 2000-12-23 Gruenenthal Chemie Formulaciones medicamentosas retardadas que contienen una combinacion de un opioide o una sal fisiologicamente tolerables del mismo, un o-agonista
DE19901687B4 (de) * 1999-01-18 2006-06-01 Grünenthal GmbH Opioide Analgetika mit kontrollierter Wirkstofffreisetzung
MXPA01007463A (es) 1999-01-29 2002-06-04 Losan Pharma Gmbh Composiciones farmaceuticas.
US6248363B1 (en) * 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
ES2226886T3 (es) 1999-08-31 2005-04-01 Grunenthal Gmbh Forma de administracion de accion retardada que contiene sacarinato de tramadol.
DE19940944B4 (de) 1999-08-31 2006-10-12 Grünenthal GmbH Retardierte, orale, pharmazeutische Darreichungsformen
DE19940740A1 (de) * 1999-08-31 2001-03-01 Gruenenthal Gmbh Pharmazeutische Salze
PE20010623A1 (es) * 1999-10-05 2001-07-07 Gruenenthal Chemie Uso de (+)-tramadol y/o o-demetiltramadol para tratamiento de urgencia urinaria incrementada y/o incontinencia urinaria
DE19947747A1 (de) 1999-10-05 2001-04-12 Gruenenthal Gmbh Verwendung von (+)-Tramadol, O-Demethyltramadol bzw. (+)-O-Demethyltramadol zur Therapie der Harninkontinenz
US6339105B1 (en) * 1999-10-12 2002-01-15 Ortho-Mcneil Pharmaceutical, Inc. Analgesic regimen
US6211229B1 (en) * 2000-02-17 2001-04-03 Neil B. Kavey Treatment of transient and short term insomnia
US6645537B2 (en) 2000-02-18 2003-11-11 Keurig, Incorporated Beverage filter cartridge
US6326404B1 (en) 2000-02-21 2001-12-04 Gruenenthal Gmbh Use of O-desmethyl-N-mono-desmethyl-tramadol
GB0007419D0 (en) * 2000-03-27 2000-05-17 Smithkline Beecham Gmbh Composition
DE10014588A1 (de) * 2000-03-27 2001-10-04 Basf Ag Wirkstoffhaltige Schwimmformen enthaltend Polyvinylacetat und Polyvinylpyrrolidon, deren Verwendung und Herstellung
DE10015479A1 (de) 2000-03-29 2001-10-11 Basf Ag Feste orale Darreichungsformen mit retardierter Wirkstofffreisetzung und hoher mechanischer Stabilität
GB0009522D0 (en) 2000-04-19 2000-06-07 Smithkline Beecham Plc Composition
US6955821B2 (en) 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
JP2001353519A (ja) * 2000-06-14 2001-12-25 Suncall Corp 二重構造クラッドパイプ及びその製造方法
DE10029201A1 (de) * 2000-06-19 2001-12-20 Basf Ag Verfahren zur Herstellung fester oraler Darreichungsformen mit retardierender Wirkstoffreisetzung
US6607748B1 (en) 2000-06-29 2003-08-19 Vincent Lenaerts Cross-linked high amylose starch for use in controlled-release pharmaceutical formulations and processes for its manufacture
DE60105243T2 (de) 2000-09-22 2005-11-24 Smb Technology Oral anzuwendende tramadolhaltige Teilchen zur einmal täglichen Verabreichung
KR101045144B1 (ko) * 2000-10-30 2011-06-30 유로-셀티크 소시에떼 아노뉨 서방성 하이드로코돈 제형
US20020106408A1 (en) * 2000-12-01 2002-08-08 Johnatan Bacon Prolamin-based sustained-release compositions and delayed-onset compositions
ATE380022T1 (de) * 2001-01-31 2007-12-15 Evonik Roehm Gmbh Multipartikuläre arzneiform, enthaltend mindestens zwei unterschiedlich überzogene pelletformen
WO2002069974A1 (en) 2001-03-05 2002-09-12 Andrew Holman Administration of sleep restorative agents
US6806293B1 (en) 2001-03-12 2004-10-19 Darley Pharmaceuticals Ltd Use of pheromone compounds having MAP kinase modulating activity
US7858118B2 (en) * 2001-04-11 2010-12-28 Galephar Pharmaceutical Research, Inc. Extended release composition containing Tramadol
US6659373B1 (en) 2001-05-30 2003-12-09 L. R. Nelson One touch actuated valve
US6968551B2 (en) 2001-06-11 2005-11-22 John Hediger System and user interface for generation and processing of software application installation instructions
US6818504B2 (en) * 2001-08-10 2004-11-16 Hynix Semiconductor America, Inc. Processes and structures for self-aligned contact non-volatile memory with peripheral transistors easily modifiable for various technologies and applications
US20030092724A1 (en) * 2001-09-18 2003-05-15 Huaihung Kao Combination sustained release-immediate release oral dosage forms with an opioid analgesic and a non-opioid analgesic
CA2466032A1 (en) 2001-10-29 2003-05-08 Laure Patricia Ouadji Njiki Methods and dosage forms for improving the bioavailability of therapeutic agents
US6863901B2 (en) * 2001-11-30 2005-03-08 Collegium Pharmaceutical, Inc. Pharmaceutical composition for compressed annular tablet with molded triturate tablet for both intraoral and oral administration
KR100540035B1 (ko) 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
ATE460933T1 (de) 2002-05-24 2010-04-15 Carl-Fr Coester Pharmazeutische wirkstoffkombination sowie deren verwendung
ATE386509T1 (de) * 2002-09-21 2008-03-15 Shuyi Zhang Formulierung von acetaminophen und tramadol mit verzögerter freisetzung
EP1558935B1 (en) 2002-10-25 2008-07-09 Labopharm Inc. Controlled-release compositions
UA84277C2 (ru) 2002-10-25 2008-10-10 Лабофарм Инк. Композиция трамадола с пролонгированным высвобождением с 24-часовым действием
TWI319713B (en) 2002-10-25 2010-01-21 Sustained-release tramadol formulations with 24-hour efficacy
US8487002B2 (en) 2002-10-25 2013-07-16 Paladin Labs Inc. Controlled-release compositions
US6669929B1 (en) * 2002-12-30 2003-12-30 Colgate Palmolive Company Dentifrice containing functional film flakes
US7413749B2 (en) * 2003-03-11 2008-08-19 Purdue Pharma L.P. Titration dosing regimen for controlled release tramadol
US20060172006A1 (en) 2003-10-10 2006-08-03 Vincent Lenaerts Sustained-release tramadol formulations with 24-hour clinical efficacy
US20050157382A1 (en) * 2004-01-07 2005-07-21 Kafka James D. Industrial directly diode-pumped ultrafast amplifier system
US20060111308A1 (en) * 2004-11-16 2006-05-25 Wendye Robbins Methods and compositions for therapeutic treatment
WO2007025005A2 (en) * 2005-08-24 2007-03-01 Penwest Pharmaceuticals Co. Sustained release formulations of nalbuphine
KR101655455B1 (ko) * 2005-09-09 2016-09-07 안젤리니 라보팜 엘엘씨 일일 1회 투여를 위한 트라조돈 조성물
US20070237816A1 (en) 2006-04-06 2007-10-11 David Finkelstein Acetaminophen formulation for joint pain relief

Also Published As

Publication number Publication date
EP1594460B1 (en) 2008-03-26
DK1594460T3 (da) 2008-07-28
NZ539870A (en) 2007-11-30
US20090047345A9 (en) 2009-02-19
DE60320039D1 (de) 2008-05-08
EP1594460A2 (en) 2005-11-16
TWI319713B (en) 2010-01-21
MXPA05004412A (es) 2005-11-23
BR0315659A (pt) 2005-09-20
US20070003618A1 (en) 2007-01-04
HK1101355A1 (en) 2007-10-18
SI1594460T1 (sl) 2008-08-31
ATE390128T1 (de) 2008-04-15
DE60320039T2 (de) 2009-05-14
US7988998B2 (en) 2011-08-02

Similar Documents

Publication Publication Date Title
UA84277C2 (ru) Композиция трамадола с пролонгированным высвобождением с 24-часовым действием
HK1101355A1 (en) Sustained-release tramadol formulations with 24-hour efficacy 24
AU2003271024A1 (en) Sustained release compound of acetamidophenol and tramadol
CY1108823T1 (el) Παραγωγα 2-υδροξυ-3-ετεροαρυλινδολης ως αναστολεις της gsk3
BR0306870A (pt) Composição farmacêutica oral, e, método para preparar a mesma
NO20100250L (no) Farmasoytisk preparat som innbefatter en S1P reseptoragonist og en sukkeralkohol, og framgangsmate til fremstilling derav
EA200600598A1 (ru) Лекарственные формы замедленного высвобождения
UA84266C2 (uk) Дозована лікарська форма у вигляді таблетки або пелети для перорального введення, яка містить інгібітор pde 4 та полівінілпіролідон, способи її одержання та застосування
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
PT1506185E (pt) Compostos novos e sua utilizacao
MXPA05007609A (es) Antagonista de un receptor sensible al calcio.
UY25234A1 (es) Formulación de liberación prolongada de venlafaxina
ECSP066291A (es) Sistemas emulsionantes que contienen derivados de azetidina
NO20050771L (no) Bicifadinformulering
HUP0104647A2 (hu) Hatóanyagként tilidin-mezilátot tartalmazó, szabályozott hatóanyag-leadású gyógyszerkészítmény
BRPI0415053A (pt) inibidor de p-glicoproteìna, método para preparar o mesmo e composição farmacêutica que compreende o mesmo
PT1105105E (pt) Forma de administracao oral para piridin-2-ilmetilsulfinil-1h-benzimidazois
RS50298B (sr) Direktno kompresibilna matrica za kontrolisano oslobađanje pojedinačnih dnevnih doza klaritromicina
AR028448A1 (es) Formulaciones que contienen una droga glucocorticoide para el tratamiento de enfermedades broncopulmonares
IS6087A (is) N-(2-fenýl-4-amínó-bútýl)-1-naftamíð sem virka á móti taugakínín-1 viðtaka
AU2001246999A1 (en) New neurokinin antagonists for use as medicaments
BR0114395A (pt) Composição farmacêutica para administração por suprimento via oral
AR039162A1 (es) Formulaciones de venlafaxina de liberacion extendida
SE0004827D0 (sv) Therapeutic compounds
AU2001244999A1 (en) Naphthamide neurokinin antagonists for use as medicaments